Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe Wiebren A. Tjalma 1 *, Alison Fiander 2 *, Olaf Reich 3 , Ned Powell 2 , Andrzej M. Nowakowski 4 , Benny Kirschner 5 , Robert Koiss 6 , John O’Leary 7 , Elmar A. Joura 8 , Mats Rosenlund 9 , Brigitte Colau 10 , Doris Schledermann 11 , Kersti Kukk 12 , Vasileia Damaskou 13 , Maria Repanti 13 , Radu Vladareanu 14 , Larisa Kolomiets 15 , Alevtina Savicheva 16 , Elena Shipitsyna 16 , Jaume Ordi 17 , Anco Molijn 18 , Wim Quint 18 , Alice Raillard 19 , Dominique Rosillon 9 , Sabrina Collas De Souza 19 , David Jenkins 20 Katsiaryna Holl 9 , for the HERACLES/SCALE Study Group 1 Department of Gynecology and Gynecologic Oncology, University Hospital Antwerpen, University of Antwerp, Antwerpen, Belgium 2 Section of Obstetrics and Gynaecology, Cardiff University School of Medicine, Wales, United Kingdom 3 Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria 4 First Department of Oncologic Gynaecology and Gynaecology, Medical University of Lublin, Lublin, Poland 5 Department of Pathology, Hvidovre University Hospital, Hvidovre, Denmark 6 Department of Obstetrics and Gynecologic Oncology, St. Stephan Hospital, Budapest, Hungary 7 CERVIVA Research Consortium, Health Research Board Ireland, Department of Pathology, The Coombe Women and Infants University Hospital and Trinity College, Dublin, Ireland 8 Comprehensive Cancer Center, Department of Gynaecology and Obstetrics, Medical University of Vienna, Vienna, Austria 9 Epidemiology Department, GlaxoSmithKline Biologicals, Wavre, Belgium 10 R&D Department, GlaxoSmithKline Biologicals, Rixensart, Belgium 11 Department of Pathology, Odense University Hospital, Odense, Denmark Key words: human papillomavirus, HPV, cervical cancer, cervical intraepithelial neoplasia, CIN Abbreviations: ADC: adenocarcinoma; AIS: adenocarcinoma in situ; ASC: adenosquamous carcinoma; CI: confidence interval; HG-CIN: high-grade cervical intraepithelial neoplasia; HPV: human papillomavirus; HR: high risk; ICC: invasive cervical cancer; LR: low risk; SCC: squamous cell carcinoma Conflict of Interest: W.A. Tjalma has received support for travel to meetings for the study or other purposes from GSK, Merck and Sanofi Pasteur. A. Fiander has been on advisory boards for both GSK and Sanofi Pasteur MSD and received research grant funding and support to attend HPV-related conferences from both companies. N. Powell’s laboratory has received funding from GSK, including for the work in support of this study; he has received honoraria from GSK and Sanofi Pasteur to speak/advise on HPV and has also received support for travel to study-related meetings. A.M. Nowakowski and his institution have been paid by GSK for participation in the study, and he has received support for travel to study-related meetings; he has also been paid by GSK and MSD for lectures. B. Kirschner has received support from GSK for travel and is a paid consultant to GSK’s Advisory Board on vaccine-related issues. J. O’Leary, V. Damaskou, M. Repanti and their institutions received funding from GSK to complete the work disclosed in this publication. E.A. Joura and his institution have received grants from GSK and Merck for HPV vaccine studies; he is also a paid member of the board of Merck (HPV vaccines), has received travel expenses from Merck, Sanofi Pasteur MSD and GSK and has also been paid by GSK, Merck and Sanofi Pasteur MSD for lectures. M. Rosenlund was employed by GSK Biologicals at the time of study; B. Colau, K. Holl and D. Rosillon are employed by GSK Biologicals; B. Colau and M. Rosenlund also have stock or stock options in GSK Biologicals. D. Schledermann has received support from GSK for congress registration and travel. A. Savicheva and E. Shipitsyna have received consulting fees or honoraria for their participation in the study and travel expenses and have previously participated in a HPV vaccine trial for GSK. The employer of A. Molijn and W. Quint, DDL Diagnostic Laboratories, has received support from GSK for travel to meetings for the study or other purposes, fees for participation in review activities such as data monitoring boards, statistical analysis and end-point committees and also grants and fees for consultancy outside the submitted work. The employer of S. Collas De Souza and A. Raillard, 4Clinics, has received consulting fees from GSK for statistical analysis. D. Jenkins was, at the time of this study, initially an employee and then consultant in HPV to GSK Biologicals. O. Reich, R. Koiss, K. Kukk, R. Vladareanu, L. Kolomiets and J. Ordi declare no conflicts of interest. Role of the funding source: The costs related to the collection of tissue and the analysis of data from both studies, together with the development of this article, were funded and coordinated by GlaxoSmithKline Biologicals. *W.A.T. and A.F. contributed equally to this work, Grant sponsor: GlaxoSmithKline Biologicals SA DOI: 10.1002/ijc.27713 History: Received 22 Aug 2011; Accepted 30 Mar 2012; Online 3 Jul 2012 Correspondence to: Wiebren A. Tjalma, Department of Gynecology and Gynecologic Oncology, University Hospital Antwerpen, Universiteit Antwerpen, Wilrijkstraat 10, 2650 Antwerp, Belgium, Fax: þ32-3-838-39-85, E-mail: wiebren.tjalma@uza.be Early Detection and Diagnosis Int. J. Cancer: 000, 000–000 (2012) V C 2012 UICC International Journal of Cancer IJC